Negative symptoms in schizophrenia: An open study placebo-fluvoxamine treatment added to neuroleptics

V. Brancato, B. Barbini, M. G. Regazzetti, C. Colombo, E. Smeraldi

Research output: Contribution to journalArticle

Abstract

Neuroleptic treatment often produces an improvement of positive symptoms in schizophrenic patients but negative ones are hardly affected. Since 1954, many studies suggest an involvement of serotoninergic system in schizophrenia, either as a deficiency or an increase of Central Nervous System serotonin (CNS 5-HT). From a clinical point of view 5-HT dysfunction was related to certain features of Crow's type II schizophrenia, such as 'negative' symptoms. Studies involving drugs which affect 5-HT system were performed with agonists and antagonists of CNS 5-HT receptors, but the results were contradictory. The authors treated twenty-three schizophrenic patients, with prevalent negative symptoms with placebo added to their previous neuroleptic therapy (four weeks) and then with a daily dose of 100 mg. of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI). Negative symptomatology significantly improved in sixteen patients while the positive ones remained unchanged.

Original languageEnglish
Pages (from-to)21-24
Number of pages4
JournalNew Trends in Experimental and Clinical Psychiatry
Volume10
Issue number1
Publication statusPublished - 1994

Fingerprint

Fluvoxamine
Antipsychotic Agents
Serotonin
Schizophrenia
Placebos
Crows
Serotonin Receptors
Serotonin Uptake Inhibitors
Therapeutics
Central Nervous System
Pharmaceutical Preparations

Keywords

  • fluvoxamine
  • negative symptoms
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Negative symptoms in schizophrenia : An open study placebo-fluvoxamine treatment added to neuroleptics. / Brancato, V.; Barbini, B.; Regazzetti, M. G.; Colombo, C.; Smeraldi, E.

In: New Trends in Experimental and Clinical Psychiatry, Vol. 10, No. 1, 1994, p. 21-24.

Research output: Contribution to journalArticle

@article{56fa6d7cad79401cbfaa4a8153b8f84b,
title = "Negative symptoms in schizophrenia: An open study placebo-fluvoxamine treatment added to neuroleptics",
abstract = "Neuroleptic treatment often produces an improvement of positive symptoms in schizophrenic patients but negative ones are hardly affected. Since 1954, many studies suggest an involvement of serotoninergic system in schizophrenia, either as a deficiency or an increase of Central Nervous System serotonin (CNS 5-HT). From a clinical point of view 5-HT dysfunction was related to certain features of Crow's type II schizophrenia, such as 'negative' symptoms. Studies involving drugs which affect 5-HT system were performed with agonists and antagonists of CNS 5-HT receptors, but the results were contradictory. The authors treated twenty-three schizophrenic patients, with prevalent negative symptoms with placebo added to their previous neuroleptic therapy (four weeks) and then with a daily dose of 100 mg. of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI). Negative symptomatology significantly improved in sixteen patients while the positive ones remained unchanged.",
keywords = "fluvoxamine, negative symptoms, schizophrenia",
author = "V. Brancato and B. Barbini and Regazzetti, {M. G.} and C. Colombo and E. Smeraldi",
year = "1994",
language = "English",
volume = "10",
pages = "21--24",
journal = "New Trends in Experimental and Clinical Psychiatry",
issn = "0393-5310",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "1",

}

TY - JOUR

T1 - Negative symptoms in schizophrenia

T2 - An open study placebo-fluvoxamine treatment added to neuroleptics

AU - Brancato, V.

AU - Barbini, B.

AU - Regazzetti, M. G.

AU - Colombo, C.

AU - Smeraldi, E.

PY - 1994

Y1 - 1994

N2 - Neuroleptic treatment often produces an improvement of positive symptoms in schizophrenic patients but negative ones are hardly affected. Since 1954, many studies suggest an involvement of serotoninergic system in schizophrenia, either as a deficiency or an increase of Central Nervous System serotonin (CNS 5-HT). From a clinical point of view 5-HT dysfunction was related to certain features of Crow's type II schizophrenia, such as 'negative' symptoms. Studies involving drugs which affect 5-HT system were performed with agonists and antagonists of CNS 5-HT receptors, but the results were contradictory. The authors treated twenty-three schizophrenic patients, with prevalent negative symptoms with placebo added to their previous neuroleptic therapy (four weeks) and then with a daily dose of 100 mg. of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI). Negative symptomatology significantly improved in sixteen patients while the positive ones remained unchanged.

AB - Neuroleptic treatment often produces an improvement of positive symptoms in schizophrenic patients but negative ones are hardly affected. Since 1954, many studies suggest an involvement of serotoninergic system in schizophrenia, either as a deficiency or an increase of Central Nervous System serotonin (CNS 5-HT). From a clinical point of view 5-HT dysfunction was related to certain features of Crow's type II schizophrenia, such as 'negative' symptoms. Studies involving drugs which affect 5-HT system were performed with agonists and antagonists of CNS 5-HT receptors, but the results were contradictory. The authors treated twenty-three schizophrenic patients, with prevalent negative symptoms with placebo added to their previous neuroleptic therapy (four weeks) and then with a daily dose of 100 mg. of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI). Negative symptomatology significantly improved in sixteen patients while the positive ones remained unchanged.

KW - fluvoxamine

KW - negative symptoms

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0028295309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028295309&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028295309

VL - 10

SP - 21

EP - 24

JO - New Trends in Experimental and Clinical Psychiatry

JF - New Trends in Experimental and Clinical Psychiatry

SN - 0393-5310

IS - 1

ER -